CARDIO- AND RENOSAFE ANTIDIABETIC THERAPY

Maximilian von Eynatten, Yan Gong, Angela Emser, Hans-Juergen Woerle, Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six phase III clinical trials. Cardiovascular Diabetology. ,vol. 12, pp. 60- 60 ,(2013) , 10.1186/1475-2840-12-60

Peter Traxler, Helmut Mett, David Raymond Stover, Jeanette Marjorie Wood, Jörg Frei, Guido Bold, Karl-Heinz Altmann, Phthalazines with angiogenesis inhibiting activity ,(1998)

Maximilian von Eynatten, Thomas Klein, Michael Mark, Yuliya Sharkovska, Berthold Hocher, Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome ,(2015)

Hans-Juergen Woerle, Odd-Erik Johansen, Thomas Klein, Eynatten Maximilian Von, Use of linagliptin in cardio- and renoprotective antidiabetic therapy ,(2014)

Jürg Dr. Zimmermann, Pyrimidin derivatives and process for their preparation ,(1993)

Bryan Burkey, Thomas Edward Hughes, Combination of organic compounds ,(2005)

Andreas Fredenhagen, Giorgio Caravatti, Staurosporine derivatives substituted at methylamino nitrogen ,(1991)

Ross A. Miller, Aaron S. Cote, Process for synthesizing a cetp inhibitor ,(2006)

Klaus Dugi, Frank Himmelsbach, Michael Mark, Uses of DPP-IV inhibitors ,(2007)

Berthold Hocher, Christoph Reichetzeder, Markus L. Alter, Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research. Kidney & Blood Pressure Research. ,vol. 36, pp. 65- 84 ,(2012) , 10.1159/000339028